Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY | Market Cap | 6.94T |
| Revenue (ttm) | 4.58T |
| Net Income (ttm) | 208.07B |
| Shares Out | 1.53B |
| EPS (ttm) | 130.16 |
| PE Ratio | 34.88 |
| Forward PE | 33.73 |
| Dividend | 196.00 (4.31%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,872,400 |
| Average Volume | 4,677,115 |
| Open | 4,560.00 |
| Previous Close | 4,540.00 |
| Day's Range | 4,515.00 - 4,573.00 |
| 52-Week Range | 3,852.00 - 4,573.00 |
| Beta | 0.41 |
| RSI | 71.33 |
| Earnings Date | May 8, 2025 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Financial Performance
In 2023, TYO:4502's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.
Financial StatementsNews
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they h...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
On Monday, Protagonist Therapeutics, Inc. (NASDAQ: PTGX) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera . Poly...
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results ...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE. 1 The Pre-Filled P...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pe...
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge
BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architect...
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO
Earnings Scheduled For January 30, 2025
Companies Reporting Before The Bell • Northrop Grumman (NYSE: NOC) is likely to report quarterly earnings at $6.35 per share on revenue of $10.97 billion. • Mobileye Global (NASDAQ: MBLY) is project...
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta...
Takeda Pharmaceutical Co Ltd (TAK) Reports Strong Q3 FY2024 Results and Announces Share Buyback
Takeda Pharmaceutical Co Ltd (TAK) Reports Strong Q3 FY2024 Results and Announces Share Buyback
Takeda Pharmaceutical Non-GAAP EPS of ¥443.00, revenue of ¥3528.2B; raises FY outlook
Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advanceme...
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
On Monday, Neurocrine Biosciences, Inc . (NASDAQ: NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
Takeda Pharmaceutical Company Limited (NYSE: TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human...
Takeda Pharmaceutical Co Ltd (TAK) Secures Approval for HYQVIA in Japan
Takeda Pharmaceutical Co Ltd (TAK) Secures Approval for HYQVIA in Japan
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hy...
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin I...
Takeda Pharmaceutical Co Ltd (TAK) Unveils Promising Late-Stage Pipeline at Investor R&D Day
Takeda Pharmaceutical Co Ltd (TAK) Unveils Promising Late-Stage Pipeline at Investor R&D Day
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Spotlights High-Value, Late-Stage Pipeline of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas.
Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors
Takeda Pharmaceutical's high dividend yield reveals risks from exchange rates, high debt, and patent expirations impacting revenue stability. Read more here.